Peginterferon lambda-1a biosimilar - Nanogen Biopharmaceutical

Drug Profile

Peginterferon lambda-1a biosimilar - Nanogen Biopharmaceutical

Alternative Names: Peglamda; Pegylated interferon lambda 1

Latest Information Update: 29 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nanogen Biopharmaceutical Co
  • Class Antivirals; Interleukins
  • Mechanism of Action Immunostimulants; Interleukin 29 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Hepatitis C
  • No development reported Hepatitis B

Most Recent Events

  • 13 Dec 2016 Peginterferon lambda-1a biosimilar is still in phase I development for Hepatitis C in Vietnam
  • 01 Jul 2016 Nanogen Biopharmaceuticals completes a phase I trial in Hepatitis C (In volunteers and Treatment-naive patients) in Vietnam (SC)
  • 14 Mar 2014 Early research in Hepatitis B in Vietnam (SC) prior to March 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top